Web Results


The time to subsequent antineoplastic therapy, time to cytotoxic chemotherapy, and chemotherapy-free survival were longer in the enzalutamide group than in the placebo group.


Prostate Cancer, PSA Doubling Time Shorter prostate-specific antigen doubling time was significantly associated with shorter metastasis-free survival and overall survival. The development of metastasis was associated with a 3-fold higher risk of death.


The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo. At primary analysis, apalutamide improved median metastasis-free survival (MFS) by 2 yr and overall survival (OS) data were immature.


Abstract. Background: We evaluated the possible use of prostate-specific antigen doubling time (PSA-DT) before chemotherapy initiation as a surrogate marker of survival in hormone-refractory prostate cancer (HRPC) patients. Patients and methods: Data from 250 consecutive metastatic HRPC patients treated with chemotherapy between February 2000 and November 2006 were retrospectively analysed.


PSA Doubling Time Predicts Metastasis, Mortality Risks in CRPC PSA in Midlife Can Predict Later Risk of Prostate Cancer Mets The median metastasis-free survival (MFS) times differed significantly ...


What the Numbers Mean. If you have a Gleason score of 5-7 Your PSA increased more than two years after surgery AND your PSA doubling time was greater than 10 months: Your chance of NOT developing metastasis (shown in bone positive scan) in:. Three years: 95 percent; Five years: 86 percent; Seven years: 82 percent; OR your PSA doubling time was less than 10 months: Your chance of NOT developing ...


If a man's PSA doubled in less than three months, his risk of dying from prostate cancer was much higher than that of a man whose PSA doubling time was more than a year. The same holds true for the time from surgery to the return of PSA: If PSA appeared on a blood test within three years after surgery, that man is at higher risk than is a man ...


An estimated 65% of these men will develop bone metastases within 10 years in the absence of salvage therapy. 2 A rapid PSA doubling time (PSADT), high-grade disease, and a short disease-free interval after radical prostatectomy are prognostic factors associated with the development of metastases in untreated patients with an increasing PSA ...


If your PSA doubled in less than three months, your risk of dying from prostate cancer is much higher than that of a patient whose PSA doubling time was more than a year. If your PSA appeared on a blood test within three years after surgery, you are at a higher risk than a patient whose PSA returns within five years.


Some evidence shows that faster-rising PSA levels may be a sign of cancer. Men who have a PSA level that doubles within a 3-month period tend to have a worse prognosis (outlook) compared to men whose PSA level does not double. This is also known as PSA doubling time. After radiation therapy